150 North Wacker Drive
Suite 2360
Chicago, IL 60606
847-381-5465 Phone
847-381-4606 Fax

User Information

Create New Account

Lost Password


Quick Links

LCDs and LCAs
by Contractor

PLA Codes

Laboratory Fee Schedule


Physician Fee Schedule


OPPS Fee Schedule


ASC Fee Schedule


APC Codes


DRG Codes


ASP Drug Pricing Files

April 2024
January 2024

CMS Transmittals

National Coverage Determination
Procedure Code: 8XXXX
Partial Thromboplastin Time (PTT)
CMS Policy Number: 190.16
Back to NCD List

Description: Basic plasma coagulation function is readily assessed with a few simple laboratory tests: The Partial Thromboplastin Time (PTT), Prothrombin Time (PT), Thrombin Time (TT), or a quantitative fibrinogen determination. The PTT test is an in vitro laboratory test used to assess the intrinsic coagulation pathway and monitor heparin therapy.

1. The PTT is most commonly used to quantitate the effect of therapeutic unfractionated heparin and to regulate its dosing. Except during transitions between heparin and warfarin therapy, in general both the PTT and PT are not necessary together to assess the effect of anticoagulation therapy. PT and PTT must be justified separately.

2. A PTT may be used to assess patients with signs or symptoms of hemorrhage or thrombosis. For example:

  • Abnormal bleeding, hemorrhage or hematoma petechiae or other signs of thrombocytopenia that could be due to Disseminated Intravascular Coagulation
  • Swollen extremity with or without prior trauma

    3. A PTT may be useful in evaluating patients who have a history of a condition known to be associated with the risk of hemorrhage or thrombosis that is related to the intrinsic coagulation pathway. Such abnormalities may be genetic or acquired. For example:

  • Dysfibrinogenemia
  • Afibrinogenemia (complete)
  • Acute or chronic liver dysfunction or failure, including Wilson’s disease
  • Hemophilia
  • Liver disease and failure
  • Infectious processes
  • Bleeding disorders
  • Disseminated intravascular coagulation
  • Lupus erythematosus or other conditions associated with circulating inhibitors, e.g., factor VIII Inhibitor, lupus-like anticoagulant
  • Sepsis
  • Von Willebrand’s disease
  • Arterial and venous thrombosis, including the evaluation of hypercoagulable states
  • Clinical conditions associated with nephrosis or renal failure
  • Other acquired and congenital coagulopathies as well as thrombotic states

    4. A PTT may be used to assess the risk of thrombosis or hemorrhage in patients who are going to have a medical intervention known to be associated with increased risk of bleeding or thrombosis. An example is as follows: evaluation prior to invasive procedures or operations of patients with personal or family history of bleeding or who are on heparin therapy

    1. The PTT is not useful in monitoring the effects of warfarin on a patient’s coagulation routinely. However, a PTT may be ordered on a patient being treated with warfarin as heparin therapy is being discontinued. A PTT may also be indicated when the PT is markedly prolonged due to warfarin toxicity.

    2. The need to repeat this test is determined by changes in the underlying medical condition and/or the dosing of heparin.

    3. Testing prior to any medical intervention associated with a risk of bleeding and thrombosis (other than thrombolytic therapy) will generally be considered medically necessary only where there are signs or symptoms of a bleeding or thrombotic abnormality or a personal history of bleeding, thrombosis or a condition associated with a coagulopathy. Hospital/clinic-specific policies, protocols, etc., in and of themselves, cannot alone justify coverage.

    To review all requirements of this policy, please see: CMS NCD listing by Chapter

    Covered ICD-10 Codes.

    A01.00Typhoid fever, unspecified
    A01.01Typhoid meningitis
    A01.02Typhoid fever with heart involvement
    A01.03Typhoid pneumonia
    A01.04Typhoid arthritis
    A01.05Typhoid osteomyelitis
    A01.09Typhoid fever with other complications
    A01.1Paratyphoid fever A
    A01.2Paratyphoid fever B
    A01.3Paratyphoid fever C
    .... and many more.

    Sorry, you need to login or register to view additional sections of this Medicare policy.

    Click here for publications catalog.

    The content and format of the following files and/or webpages are copywritten and the property of Wheaton Partners, LLC - dba CodeMap®. All recipients of these files agree not to distribute, reproduce and/or use the information contained within, in any manner not expressly agreed upon by the user and Wheaton Partners, LLC - dba CodeMap®.

    All code-pairs and Medicare coverage information are compiled directly from Center for Medicare and Medicaid Services (CMS) and Medicare Contractor coverage policies. CodeMap® has made every reasonable effort to ensure the accuracy of the information contained. However, the ultimate responsibility for correct coding and claims submission lies with the provider of services. Both CMS and Medicare contractor coverage policy information may change at any time. CodeMap® makes no representation, warranty, or guarantee that this compilation of coverage policy information is error-free or that the use of this information will result in Medicare coverage and subsequent payment of claims. Final coverage and payment of claims are subject to many factors exclusively controlled by CMS and its contractors.

  • CodeMap® is a Registered Trademark of Wheaton Partners, LLC.